title: FluBlok, a recombinant hemagglutinin influenza vaccine.
abstract: FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
authors.affiliation: Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA. manon.cox@proteinsciences.com
authors.forename: Manon M J
authors.initials: MM
authors.lastname: Cox
authors.forename: Peter A
authors.initials: PA
authors.lastname: Patriarca
authors.forename: John
authors.initials: J
authors.lastname: Treanor
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000008:administration & dosage; D014481:United States; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
chemical_list: C528512:FluBlok; D007252:Influenza Vaccines; D010919:Placebos; D014614:Vaccines, Synthetic